Qlife CE-marks COVID-19 test

Report this content

Qlife announces that the company has CE-marked its PCR test for Sars-CoV-2 for professional use on the mobile test platform Egoo.Health and that the commercialization can begin immediately.

The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market. The next step is to place the COVID-19 test in strategic locations, where it can offer fast and reliable results with help from healthcare professionals.

“With this CE-marking, Qlife has achieved an important regulatory milestone. Our COVID-19-test is one of the first mobile PCR tests that can offer exactly the same clinical quality as laboratories. Now, we can really start the commercial rollout of our mobile test and make it available to a much larger target group and in environments where testing continuously must be done by healthcare professionals", says Thomas Warthoe, CEO of Qlife.

The CE-mark covers the test platform Egoo.Health, i.e. mobile test unit, disposable capsules and software. The CE-mark enables the commercialization to begin immediately.

For more information please contact:

Thomas Warthoe, CEO
+45 21 63 35 34

About Qlife

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

This information is insider information that Qlife Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 on January 7, 2021.